Tempus AI Surges Since IPO as FDA Clearance Boosts Growth Outlook

Tempus AI, Inc. (NASDAQ:TEM) is one of the 11 Best Performing IPOs in the Last 2 Years.

The stock’s price target is raised following a strong second quarter and FDA approval for Tempus Pixel.

On August 08, 2025, Tempus AI, Inc. (NASDAQ:TEM) reported a second-quarter 2025 revenue of $314.6 million, an increase of 89.6%. The growth was attributed to a 115% increase in Genomics revenue driven by strong oncology volume growth. Later, on September 11, 2025, the company also announced acquiring 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its updated Tempus Pixel. This AI-powered cardiac imaging platform’s new update allows the generation of T1 and T2 inline maps, thus optimizing the device’s capabilities for cardiac MR image analysis.

Following these developments, H.C. Wainwright raised the stock’s price target from $90 to $98, while maintaining the Buy rating, signaling an upside potential for the stock. Since its IPO, the company has achieved a notable growth of 111.50%, adding to its positive outlook.

Tempus AI, Inc. (NASDAQ:TEM) was founded in 2015 and is headquartered in Illinois. Established under the healthcare technology sector, the company is a leader in applying artificial intelligence to clinical and molecular data to advance precision medicine, thus creating more effective treatments for patients.

While we acknowledge the potential of TEM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 13 Best Freight Stocks to Invest in Now and 12 Jim Cramer Stock Picks this Week

Disclosure. None.